Donor-derived cell-free DNA (dd-cfDNA) is a biomarker for rejection after organ transplantation. We hypothesized that high release of cfDNA immediately after liver transplant also has a biologic role in inflammation in ischemia and reperfusion injury (IRI). To investigate this concept, C57BL/6 mice were subjected to 90 min in situ liver ischemia. After 6 h reperfusion, cfDNA was purified from serum and used to stimulate macrophages in vitro , which resulted in production of high levels of inflammatory cytokines TNFα and IL-6, and chemokine CXCL10. Enzymatic degradation of cfDNA by DNase I inhibited these inflammatory responses (e.g., TNFα: DNase I 48.1 ± 37.4 vs. untreated 1,030 ± 206 pg/mL, p = 0.0001). cfDNA from netosis-deficient PAD4KO mice was found to be equally pro-inflammatory compared to wild type cfDNA (TNFα: PAD4KO 1048 ± 199 vs. wild-type 1,162 ± 150 pg/mL, p = 0.64), indicating its mechanism is not dependent on neutrophils undergoing netosis. Next, a single dose of DNase I was added to the perfusate during rat liver normothermic machine perfusion (NMP) to significantly reduce perfusate cfDNA levels (384 ± 132 to 129 ± 18 ng/mL, p = 0.026). In conclusion, our data suggest that cfDNA can have pro-inflammatory effects during liver IRI beyond being a biomarker. DNase I may be a promising therapeutic intervention during NMP to reduce the graft’s inflammatory propensity prior to implantation.
Schnepppfister et al. (Wed,) studied this question.